Research Analysts Issue Forecasts for EPRX FY2026 Earnings

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Stock analysts at HC Wainwright increased their FY2026 EPS estimates for Eupraxia Pharmaceuticals in a note issued to investors on Wednesday, November 11th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($0.96) for the year, up from their previous estimate of ($0.98). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($1.23) EPS, FY2029 earnings at ($0.96) EPS and FY2030 earnings at $0.14 EPS.

A number of other equities analysts have also recently weighed in on EPRX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 8th. Oppenheimer reaffirmed an “outperform” rating on shares of Eupraxia Pharmaceuticals in a research note on Tuesday, October 20th. Stifel Nicolaus set a $25.00 target price on Eupraxia Pharmaceuticals in a research note on Thursday, September 24th. Wall Street Zen lowered Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Sunday, November 8th. Finally, Royal Bank Of Canada started coverage on shares of Eupraxia Pharmaceuticals in a research note on Monday. They issued an “outperform” rating and a $14.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Eupraxia Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Eupraxia Pharmaceuticals Stock Down 3.1%

EPRX stock opened at $7.81 on Friday. Eupraxia Pharmaceuticals has a 52-week low of $5.63 and a 52-week high of $9.32. The company has a debt-to-equity ratio of 0.03, a current ratio of 12.25 and a quick ratio of 16.00. The company’s 50-day simple moving average is $7.63 and its 200-day simple moving average is $7.25.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.03.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Persistent Asset Partners Ltd acquired a new stake in Eupraxia Pharmaceuticals during the 2nd quarter worth $25,000. BlackRock Inc. acquired a new position in Eupraxia Pharmaceuticals during the second quarter worth about $40,000. China Universal Asset Management Co. Ltd. boosted its position in Eupraxia Pharmaceuticals by 28.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company’s stock worth $133,000 after acquiring an additional 3,500 shares during the last quarter. AXQ Capital LP grew its stake in Eupraxia Pharmaceuticals by 34.2% during the 2nd quarter. AXQ Capital LP now owns 21,150 shares of the company’s stock valued at $140,000 after acquiring an additional 5,390 shares in the last quarter. Finally, Ingalls & Snyder LLC raised its holdings in Eupraxia Pharmaceuticals by 10.2% in the 3rd quarter. Ingalls & Snyder LLC now owns 75,450 shares of the company’s stock valued at $687,000 after acquiring an additional 7,000 shares during the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues. The company’s lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.